{"organizations": [], "uuid": "4c513f7926ab9151d8bdf76b1ada461bcbb4569b", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-johnson-johnson-reports-2017-q4-lo/brief-johnson-johnson-reports-2017-q4-loss-of-3-99-per-share-idUSASB0C1UC", "country": "US", "domain_rank": 408, "title": "BRIEF-Johnson & Johnson Reports 2017 Q4 Loss Of $3.99 Per Share", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-23T13:52:00.000+02:00", "replies_count": 0, "uuid": "4c513f7926ab9151d8bdf76b1ada461bcbb4569b"}, "author": "", "url": "https://www.reuters.com/article/brief-johnson-johnson-reports-2017-q4-lo/brief-johnson-johnson-reports-2017-q4-loss-of-3-99-per-share-idUSASB0C1UC", "ord_in_thread": 0, "title": "BRIEF-Johnson & Johnson Reports 2017 Q4 Loss Of $3.99 Per Share", "locations": [], "entities": {"persons": [{"name": "johnson", "sentiment": "none"}], "locations": [], "organizations": [{"name": "brief-johnson & johnson reports", "sentiment": "negative"}, {"name": "brief-johnson & johnson", "sentiment": "negative"}, {"name": "reuters", "sentiment": "none"}, {"name": "thomson reuters", "sentiment": "none"}, {"name": "j&j", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "January 23, 2018 / 11:52 AM / in 10 minutes BRIEF-Johnson & Johnson Reports 2017 Q4 Loss Of $3.99 Per Share Reuters Staff \nJan 23 (Reuters) - Johnson & Johnson: * REPORTS 2017 FOURTH-QUARTER RESULTS: * SEES FY 2018 ADJUSTED EARNINGS PER SHARE $8.00 TO $8.20 * SEES FY 2018 SALES $80.6 BILLION TO $81.4 BILLION * SEES FY 2018 SALES UP 3.5 TO 4.5 PERCENT \n* J&J - 2017 FOURTH-QUARTER SALES OF $20.2 BILLION INCREASED 11.5%; EPS WAS A LOSS OF $3.99 \n* Q4 EARNINGS PER SHARE VIEW $1.72, REVENUE VIEW $20.07 BILLION -- THOMSON REUTERS I/B/E/S * J&J - ADJUSTED 2017 FOURTH-QUARTER EPS WAS $1.74 \n* J&J - ‍​ COMPANY RECORDS SPECIAL ITEM CHARGE OF APPROXIMATELY $13.6 BILLION RELATED TO RECENTLY ENACTED TAX LEGISLATION \n* J&J - EXCLUDING NET IMPACT OF ACQUISITIONS AND DIVESTITURES, ON OPERATIONAL BASIS, WORLDWIDE SALES FOR Q4 INCREASED 4.2% \n* Q4 EARNINGS PER SHARE VIEW $1.72, REVENUE VIEW $20.07 BILLION -- THOMSON REUTERS I/B/E/S \n* J&J - QTRLY WORLDWIDE CONSUMER SALES OF $3,540 MILLION VERSUS $3,432 MILLION \n* J&J QTRLY WORLDWIDE VELCADE SALES $271 MILLION VERSUS $273 MILLION IN Q3 2017 \n* J&J - QTRLY WORLDWIDE PHARMACEUTICAL SALES OF $9,681 MILLION VERSUS $8,232 MILLION \n* J&J - EXCLUDING NET IMPACT OF ACQUISITIONS, DIVESTITURES, ON OPERATIONAL BASIS, DOMESTIC SALES ROSE 4.1% AND INTERNATIONAL SALES ROSE 4.3% IN QUARTER \n* FY2018 EARNINGS PER SHARE VIEW $7.87, REVENUE VIEW $80.70 BILLION -- THOMSON REUTERS I/B/E/S \n* J&J QTRLY WORLDWIDE ZYTIGA SALES $755 MILLION VERSUS $669 MILLION IN Q3 2017 \n* J&J - QTRLY WORLDWIDE MEDICAL DEVICES SALES OF $6,974 MILLION VERSUS $6,442 MILLION \n* J&J QTRLY WORLDWIDE REMICADE SALES $1,466 MILLION VERSUS $1,647 MILLION IN Q3 \n* J&J QTRLY WORLDWIDE INVOKANA/INVOKAMET SALES $267 MILLION VERSUS $265 MILLION IN Q3 2017 Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-01-23T13:52:00.000+02:00", "crawled": "2018-01-23T14:08:25.081+02:00", "highlightTitle": ""}